Ondansetron HCl
Ondansetron HCl (Hydrochloride) is a selective 5-HT3 receptor antagonist active pharmaceutical ingredient widely used for the prevention and treatment of nausea and vomiting associated with chemotherapy, radiotherapy, and postoperative recovery. By blocking serotonin receptors in the central nervous system and gastrointestinal tract, Ondansetron HCl reduces the vomiting reflex and provides effective symptom relief. Its rapid onset and favorable safety profile make it a preferred therapy in both adult and pediatric patients. Pharmaceutical companies formulate Ondansetron HCl into oral tablets, oral disintegrating tablets, and injectable solutions, providing flexible dosing options for diverse clinical needs.
Common Ondansetron HCl Uses and Treated Conditions
- Chemotherapy-Induced Nausea and Vomiting – Prevents acute and delayed emesis in cancer patients.
- Postoperative Nausea and Vomiting – Reduces nausea and vomiting following surgical procedures.
- Radiotherapy-Induced Nausea – Manages emesis in patients undergoing radiation therapy.
- Adjunct Antiemetic Therapy – Used alongside other antiemetics for enhanced control of severe nausea.
Why Choose Cambrex as Your Generic API Manufacturer?
As a leading generic API supplier, Cambrex manufactures Ondansetron HCl API in cGMP-compliant facilities, ensuring every batch meets stringent global quality and regulatory standards. Our technical expertise, robust quality systems, and proven regulatory track record empower clients to accelerate development timelines and achieve successful market approvals. We prioritize transparency, reliability, and scientific rigor at every stage of the supply chain making us your trusted generic API manufacturer.
For detailed chemical information on Ondansetron HCl, visit the official CAS website.
If you’d like more information or to request a sample, contact our Generic API team today.

Cambrex your API partner
Cambrex are a leading global supplier of generic APIs. From our sites in Italy, Sweden, and the USA, we work with generic drug companies well in advance of drug patent expiration, using high quality, non-patent-infringing processes to manufacture APIs.
Contact us